GlycoMimetics, Inc. (GLYC): Price and Financial Metrics
GLYC Price/Volume Stats
| Current price | $1.43 | 52-week high | $4.16 |
| Prev. close | $1.50 | 52-week low | $0.55 |
| Day low | $1.43 | Volume | 37,865 |
| Day high | $1.51 | Avg. volume | 598,872 |
| 50-day MA | $1.55 | Dividend yield | N/A |
| 200-day MA | $1.86 | Market Cap | 91.98M |
GLYC Stock Price Chart Interactive Chart >
GLYC POWR Grades
- GLYC scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.31% of US stocks.
- GLYC's strongest trending metric is Growth; it's been moving down over the last 178 days.
- GLYC's current lowest rank is in the Momentum metric (where it is better than 4.59% of US stocks).
GLYC Stock Summary
- The ratio of debt to operating expenses for GLYCOMIMETICS INC is higher than it is for about merely 5.68% of US stocks.
- GLYC's price/sales ratio is 1,404.84; that's higher than the P/S ratio of 99.53% of US stocks.
- With a year-over-year growth in debt of -61.21%, GLYCOMIMETICS INC's debt growth rate surpasses just 4.13% of about US stocks.
- If you're looking for stocks that are quantitatively similar to GLYCOMIMETICS INC, a group of peers worth examining would be PLSE, IPWR, LOOP, OVID, and PTGX.
- GLYC's SEC filings can be seen here. And to visit GLYCOMIMETICS INC's official web site, go to www.glycomimetics.com.
GLYC Valuation Summary
- In comparison to the median Healthcare stock, GLYC's price/sales ratio is 29063.83% higher, now standing at 1370.7.
- Over the past 116 months, GLYC's EV/EBIT ratio has gone down 36.5.
Below are key valuation metrics over time for GLYC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GLYC | 2023-07-26 | 1370.7 | 1.7 | -2.4 | -0.9 |
| GLYC | 2023-07-25 | 1388.0 | 1.7 | -2.5 | -0.9 |
| GLYC | 2023-07-24 | 1405.3 | 1.7 | -2.5 | -1.0 |
| GLYC | 2023-07-21 | 1421.3 | 1.7 | -2.5 | -1.0 |
| GLYC | 2023-07-20 | 1400.0 | 1.7 | -2.5 | -1.0 |
| GLYC | 2023-07-19 | 1370.7 | 1.7 | -2.4 | -0.9 |
GLYC Growth Metrics
- The 3 year cash and equivalents growth rate now stands at -60.86%.
- The 5 year price growth rate now stands at -31.36%.
- The 2 year cash and equivalents growth rate now stands at -50.56%.
The table below shows GLYC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.092625 | -51.35248 | -53.86624 |
| 2022-06-30 | 0.179185 | -59.68164 | -62.67473 |
| 2022-03-31 | 0.104327 | -57.0624 | -63.80642 |
| 2021-12-31 | 1.159767 | -57.48953 | -63.42744 |
| 2021-09-30 | 1.305078 | -54.369 | -61.56838 |
| 2021-06-30 | 2.218518 | -48.92658 | -57.95859 |
GLYC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GLYC has a Quality Grade of C, ranking ahead of 40.69% of graded US stocks.
- GLYC's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
- VIRX, BLCM, and NAII are the stocks whose asset turnover ratios are most correlated with GLYC.
The table below shows GLYC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.010 | 1 | 23.374 |
| 2021-06-30 | 0.016 | 1 | 27.959 |
| 2021-03-31 | 0.015 | 1 | 58.956 |
| 2020-12-31 | 0.066 | 1 | 181.126 |
| 2020-09-30 | 0.063 | 1 | -39.165 |
| 2020-06-30 | 0.054 | 1 | -27.549 |
GLYC Price Target
For more insight on analysts targets of GLYC, see our GLYC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.67 | Average Broker Recommendation | 1.62 (Moderate Buy) |
GlycoMimetics, Inc. (GLYC) Company Bio
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. The company was founded in 2003 and is based in Rockville, Maryland.
Latest GLYC News From Around the Web
Below are the latest news stories about GLYCOMIMETICS INC that investors may wish to consider to help them evaluate GLYC as an investment opportunity.
GlycoMimetics Insiders Placed Bullish Bets Worth US$890kIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687ROCKVILLE, Md., September 06, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics. |
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceROCKVILLE, Md., September 05, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. |
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)ROCKVILLE, Md., August 17, 2023--GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to purchase an aggregate of 110,000 shares to Gaetano Bonifacio, M.D., the Company’s new Vice President, Global Medical Affairs. The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan in |
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023ROCKVILLE, Md., August 02, 2023--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023. Cash and cash equivalents as of June 30, 2023 were $58.0 million. |
GLYC Price Returns
| 1-mo | -8.92% |
| 3-mo | N/A |
| 6-mo | 17.21% |
| 1-year | 159.20% |
| 3-year | -54.31% |
| 5-year | -90.28% |
| YTD | -52.81% |
| 2022 | 110.42% |
| 2021 | -61.70% |
| 2020 | -28.92% |
| 2019 | -44.14% |
| 2018 | -43.60% |
Loading social stream, please wait...